RxDoctor Payments Data

Mushtaq Mohammed, MD

Hospitalist · Bolingbrook, ILNPI 1700828563

Payments from drug & device makers

$825in general payments, 2019–2025

Across 21 payments — averaging $39.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$314
  • Edwards Lifesciences$141
  • Mallinckrodt Hospital Products Inc.$98
  • Aurinia Pharma U.S., Inc.$72
  • AstraZeneca$63
  • Enterra Medical, Inc.$36
  • plus $101 from 4 others

What the payments were for

  • Food & beverage$825100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$825 in reported general payments places this provider in the 90th percentile of 1,328 hospitalist providers in Illinois.

See all hospitalist providers in Illinois

Medicare billing

Part B allowed, 2024
$553,973
Medicare patients
613
Services billed
5,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban592$184,171
XifaxanRifaximin14$43,668
XareltoRivaroxaban116$33,740
JardianceEmpagliflozin50$17,098
JanuviaSitagliptin Phosphate53$15,465
TrulicityDulaglutide55$14,941
Atorvastatin Calcium658$12,509
Memantine Hcl222$11,546
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam61$9,879
Vancomycin Hcl59$9,335
Potassium Chloride360$8,406
GemtesaVibegron28$8,321
Sucralfate75$8,083
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog95$7,915
Pantoprazole Sodium222$7,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$63$6,88579 claims
Novo NordiskFiasp$21$4,15413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,328 hospitalist providers in Illinois.

Other hospitalist in Bolingbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →